How does a symmetric dimer recognize an asymmetric substrate? A substrate complex of HIV-1 protease.

The crystal structure of an actual HIV-1 protease-substrate complex is presented at 2.0 A resolution (R-value of 19.7 % (R(free) 23.3 %)) between an inactive variant (D25N) of HIV-1 protease and a long substrate peptide, Lys-Ala-Arg-Val-Leu-Ala-Glu-Ala-Met-Ser, which covers a full binding epitope of capsid(CA)-p2, cleavage site. The substrate peptide is asymmetric in both size and charge distribution. To accommodate this asymmetry the two protease monomers adopt different conformations burying a total of 1038 A(2) of surface area at the protease-substrate interface. The specificity for the CA-p2 substrate peptide is mainly hydrophobic, as most of the hydrogen bonds are made with the backbone of the peptide substrate. Two water molecules bridge the two monomers through the loops Gly49-Gly52 (Gly49'-Gly52') and Pro79'-Val82' (Pro79-Val82). When other complexes are compared, the mobility of these loops is correlated with the content of the P1 and P1' sites. Interdependence of the conformational changes allows the protease to exhibit its wide range of substrate specificity.

[1]  G J Williams,et al.  The Protein Data Bank: a computer-based archival file for macromolecular structures. , 1977, Journal of molecular biology.

[2]  Marianne Manchester,et al.  Complete mutagenesis of the HIV-1 protease , 1989, Nature.

[3]  M. Lawrence,et al.  Shape complementarity at protein/protein interfaces. , 1993, Journal of molecular biology.

[4]  A Wlodawer,et al.  Energy calculations and analysis of HIV-1 protease-inhibitor crystal structures. , 1994, Protein engineering.

[5]  A Wlodawer,et al.  Structure of complex of synthetic HIV-1 protease with a substrate-based inhibitor at 2.3 A resolution. , 1989, Science.

[6]  R. Weiss.  Human Retroviruses, Cancer, and AIDS. Approaches to Prevention and Therapy , 1988 .

[7]  A Wlodawer,et al.  Structure at 2.5-A resolution of chemically synthesized human immunodeficiency virus type 1 protease complexed with a hydroxyethylene-based inhibitor. , 1991, Biochemistry.

[8]  R J Read,et al.  Crystallography & NMR system: A new software suite for macromolecular structure determination. , 1998, Acta crystallographica. Section D, Biological crystallography.

[9]  R M Stroud,et al.  Domain flexibility in retroviral proteases: structural implications for drug resistant mutations. , 1998, Biochemistry.

[10]  M. Jaskólski,et al.  Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease. , 1989, Science.

[11]  Crystallographic analysis of human immunodeficiency virus 1 protease with an analog of the conserved CA-p2 substrate -- interactions with frequently occurring glutamic acid residue at P2' position of substrates. , 1997 .

[12]  G. N. Ramachandran,et al.  Conformation of polypeptides and proteins. , 1968, Advances in protein chemistry.

[13]  R. Stroud,et al.  Three-dimensional structures of HIV-1 and SIV protease product complexes. , 1996, Biochemistry.

[14]  K. Murthy,et al.  The crystal structures at 2.2-A resolution of hydroxyethylene-based inhibitors bound to human immunodeficiency virus type 1 protease show that the inhibitors are present in two distinct orientations. , 1994 .

[15]  K. Chou,et al.  Predicting human immunodeficiency virus protease cleavage sites in proteins by a discriminant function method , 1996, Proteins.

[16]  L. Babe,et al.  Defining the Level of Human Immunodeficiency Virus Type 1 ( HIV-1 ) Protease Activity Required for HIV-1 Particle Maturation and Infectivity , 1995 .

[17]  T. Bhat,et al.  Crystal structure of a tethered dimer of HIV-1 proteinase complexed with an inhibitor , 1994, Nature Structural Biology.

[18]  L J Davis,et al.  Active human immunodeficiency virus protease is required for viral infectivity. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[19]  M. Hatada,et al.  Novel binding mode of highly potent HIV-proteinase inhibitors incorporating the (R)-hydroxyethylamine isostere. , 1991, Journal of medicinal chemistry.

[20]  A. Wlodawer,et al.  Crystal structures of the inactive D30N mutant of feline immunodeficiency virus protease complexed with a substrate and an inhibitor. , 1997, Biochemistry.

[21]  S Foundling,et al.  Crystal structures of complexes of a peptidic inhibitor with wild-type and two mutant HIV-1 proteases. , 1996, Biochemistry.

[22]  A M Hassell,et al.  Hydroxyethylene isostere inhibitors of human immunodeficiency virus-1 protease: structure-activity analysis using enzyme kinetics, X-ray crystallography, and infected T-cell assays. , 1992, Biochemistry.

[23]  J. Thornton,et al.  PROCHECK: a program to check the stereochemical quality of protein structures , 1993 .

[24]  Conrad C. Huang,et al.  The MIDAS display system , 1988 .

[25]  R. Dixon,et al.  Crystallographic analysis of a complex between human immunodeficiency virus type 1 protease and acetyl-pepstatin at 2.0-A resolution. , 1991, The Journal of biological chemistry.

[26]  J. Martin,et al.  Molecular recognition of macrocyclic peptidomimetic inhibitors by HIV-1 protease. , 1999, Biochemistry.

[27]  J. Sack,et al.  CHAIN — A crystallographic modeling program , 1988 .

[28]  Dale J. Kempf,et al.  Influence of Stereochemistry on Activity and Binding Modes for C2 Symmetry-Based Diol Inhibitors of HIV-1 Protease , 1994 .

[29]  A. Brunger.  Free R value: a novel statistical quantity for assessing the accuracy of crystal structures. , 1992 .

[30]  A Wlodawer,et al.  X-ray crystallographic structure of a complex between a synthetic protease of human immunodeficiency virus 1 and a substrate-based hydroxyethylamine inhibitor. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[31]  Alexander Wlodawer,et al.  Database of three-dimensional structures of HIV proteinases , 1997, Nature Structural Biology.

[32]  D. P. Brunner,et al.  Large scale purification and refolding of HIV-1 protease fromEscherichia coli inclusion bodies , 1993, Journal of protein chemistry.

[33]  T. Bhat,et al.  Structure of HIV-1 protease with KNI-272, a tight-binding transition-state analog containing allophenylnorstatine. , 1995, Structure.

[34]  K. Sharp,et al.  Protein folding and association: Insights from the interfacial and thermodynamic properties of hydrocarbons , 1991, Proteins.

[35]  L. Babe,et al.  Trans-dominant inhibitory human immunodeficiency virus type 1 protease monomers prevent protease activation and virion maturation. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[36]  Narmada Thanki,et al.  Crystal structure of a complex of HIV‐1 protease with a dihydroxyethylene‐containing inhibitor: Comparisons with molecular modeling , 1992, Protein science : a publication of the Protein Society.

[37]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[38]  R. DesJarlais,et al.  Inhibition of human immunodeficiency virus-1 protease by a C2-symmetric phosphinate. Synthesis and crystallographic analysis. , 1993, Biochemistry.

[39]  R E Cachau,et al.  Inhibition and catalytic mechanism of HIV-1 aspartic protease. , 1996, Journal of molecular biology.

[40]  M G Grütter,et al.  Comparative analysis of the X-ray structures of HIV-1 and HIV-2 proteases in complex with CGP 53820, a novel pseudosymmetric inhibitor. , 1995, Structure.

[41]  C. Flexner.  HIV-protease inhibitors. , 1998, The New England journal of medicine.

[42]  A. Wlodawer,et al.  Structure-based inhibitors of HIV-1 protease. , 1993, Annual review of biochemistry.

[43]  B. Lee,et al.  The interpretation of protein structures: estimation of static accessibility. , 1971, Journal of molecular biology.

[44]  J. Erickson,et al.  Structural mechanisms of HIV drug resistance. , 1996, Annual review of pharmacology and toxicology.

[45]  T. Robins,et al.  HIV protease inhibitors: their anti-HIV activity and potential role in treatment. , 1993, Journal of acquired immune deficiency syndromes.